figshare
Browse
SatSept140.pdf (662.17 kB)

Natural anti-A and Tn-cross-reactive IgM arise from developmental O-GalNAc glycosylations.*

Download (126.47 MB)
Version 351 2017-05-03, 16:20
Version 350 2017-05-02, 11:08
Version 349 2017-05-01, 21:04
Version 348 2017-03-02, 14:32
Version 347 2017-02-26, 23:21
Version 346 2017-02-26, 22:56
Version 345 2017-02-26, 19:33
Version 344 2017-02-26, 11:27
Version 343 2017-02-23, 21:30
Version 342 2017-01-24, 15:14
Version 341 2017-01-07, 00:13
Version 340 2016-12-22, 15:49
Version 339 2016-12-22, 15:42
Version 338 2016-12-21, 23:57
Version 337 2016-12-21, 16:44
Version 336 2016-12-21, 09:42
Version 335 2016-12-20, 14:18
Version 334 2016-12-20, 09:56
Version 333 2016-11-21, 11:36
Version 332 2016-11-10, 09:59
journal contribution
posted on 2017-05-03, 16:20 authored by Peter ArendPeter Arend

While native blood group A-like glycans have not been demonstrated in prokaryotic microorganisms as a source of human “natural” anti-A isoagglutinin production, and metazoan O-GalNAc-Ser/Thr glycosylations do not occur in bacteria and plants, the O-GalNAc glycan-bearing ovarian glycolipids, discovered in C57BL/10 mice, are complementary to the syngeneic anti-A-reactive immunoglobulin M (IgM), which is not present in animals that have undergone ovariectomy prior to the onset of puberty. These mammalian ovarian glycolipids are complementary also to the anti-A/Tn cross-reactive Helix pomatia agglutinin (HPA), a molluscan defense protein, emerging from the coat proteins of fertilized eggs and reflecting the snail-intrinsic, reversible O-GalNAc glycosylations. The hexameric structure of this primitive invertebrate defense protein gives rise to speculation regarding an evolutionary relationship to the mammalian non-immune, anti-A-reactive immunoglobulin M (IgM) molecule. Hypothetically, this molecule obtains its complementarity from the first step of protein glycosylations, initiated in metazoans by GalNAc via transient O-linkages, whereas the subsequent transferase depletion completes germ cell maturation and cell renewal, and causes the loss of glycosidic bonds and release of O-glycan-depleted proteins, such as complementary IgM revealing the structure of the volatilely expressed “lost” glycan carrier through germline-specific Ser residues. Consequently, the evolutionary/developmental, first glycosylations of proteins appear metabolically related or identical to that of the mucin-type, potentially “aberrant” monosaccharide GalNAcα1-O-Ser/Thr-R, also referred to as the Tn (T “nouvelle”) antigen, and explain the anti-Tn cross-reactivity of human innate or "natural" anti-A-specific isoagglutinin and the pronounced occurrence of cross-reactive anti-Tn antibody in plasma from humans with histo-blood group O. In fact, A-allelic, phenotype-specific GalNAc glycosylation of plasma proteins does not occur in human blood group O, affecting anti-Tn antibody levels, which may function as a growth regulator that contributes to a potential survival advantage of this group in the overall risk of developing cancer when compared with non-O blood groups.

*This article is part and preprint version of: Arend, P. Early ovariectomy reveals the germline encoding of natural anti-A-and Tn-cross-reactive immunoglobulin M (IgM) arising from developmental O-GalNAc glycosylations. ( Germline-encoded natural anti-A and anti-Tn-reactive IgM) 2017; Cancer Medicine in press, doi: 10.1002/cam4.1079

History